{"id":5642,"date":"2023-12-01T12:02:25","date_gmt":"2023-12-01T17:02:25","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5642"},"modified":"2026-04-08T14:30:58","modified_gmt":"2026-04-08T18:30:58","slug":"aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","title":{"rendered":"Cas d'Utilisation d'Aptamarqueur : Am\u00e9liorer les Essais Cliniques avec la Pr\u00e9cision d'Aptamarqueur - Personnaliser les Crit\u00e8res d'Inclusion et d'Exclusion"},"content":{"rendered":"<ul>\n<li>La plateforme Aptamarker de NeoVentures Biotechnology r\u00e9volutionne les essais cliniques en introduisant des crit\u00e8res d'inclusion et d'exclusion personnalis\u00e9s et pr\u00e9dictifs.<\/li>\n<li>Les Aptamarkers sont form\u00e9s \u00e0 l'aide d'\u00e9chantillons biologiques et des r\u00e9ponses au traitement des participants, permettant ainsi un test qPCR rentable pour le d\u00e9pistage des individus entrant dans les essais cliniques.<\/li>\n<li>Les capacit\u00e9s pr\u00e9dictives des Aptamarkers permettent aux chercheurs de personnaliser les crit\u00e8res d'inclusion pour les r\u00e9ponses positives au traitement et les crit\u00e8res d'exclusion pour ceux susceptibles de pr\u00e9senter des effets secondaires, am\u00e9liorant ainsi les taux de r\u00e9ussite des essais, la s\u00e9curit\u00e9 des participants et l'efficacit\u00e9 globale du d\u00e9veloppement de m\u00e9dicaments.<\/li>\n<\/ul>\n<p>Les essais cliniques sont des \u00e9tapes cruciales dans le d\u00e9veloppement de m\u00e9dicaments, fournissant des informations inestimables sur l'efficacit\u00e9 et la s\u00e9curit\u00e9 d'un traitement. L'approche traditionnelle de la conception des essais cliniques consiste \u00e0 d\u00e9finir des crit\u00e8res d'inclusion et d'exclusion stricts bas\u00e9s sur les caract\u00e9ristiques de la population g\u00e9n\u00e9rale. Cependant, la nature dynamique des r\u00e9ponses individuelles aux traitements n\u00e9cessite une strat\u00e9gie plus personnalis\u00e9e et pr\u00e9dictive. La plateforme Aptamarker de NeoVentures Biotechnology r\u00e9volutionne le paysage des essais cliniques en offrant une solution sophistiqu\u00e9e pour personnaliser les crit\u00e8res d'inclusion et d'exclusion avec une pr\u00e9cision sans pr\u00e9c\u00e9dent.<\/p>\n<h2>Les dynamiques des essais cliniques<\/h2>\n<p>Le c\u0153ur des essais cliniques r\u00e9side dans la g\u00e9n\u00e9ration de nouvelles informations, mais le parcours n'est pas uniforme pour chaque participant. Certains individus peuvent \u00e9prouver des effets secondaires inattendus, tandis que d'autres peuvent r\u00e9pondre exceptionnellement bien au traitement. Reconnaissant cette variabilit\u00e9, Aptamarker introduit un changement de paradigme en permettant la formation d'aptamarkers pour pr\u00e9dire les r\u00e9sultats individuels des essais cliniques.<\/p>\n<h2>Formation d'Aptamarkers pour des Pr\u00e9dictions Personnalis\u00e9es<\/h2>\n<p>Le processus commence par l'application de la biblioth\u00e8que d'Aptamarkers \u00e0 des \u00e9chantillons biologiques pr\u00e9lev\u00e9s sur des individus participant \u00e0 un essai clinique. Cette application pr\u00e9alable permet de comprendre la situation biomol\u00e9culaire de base des participants. Simultan\u00e9ment, la plateforme n\u00e9cessite des informations sur les r\u00e9actions de ces individus au traitement pendant l'essai. Cette approche \u00e0 double entr\u00e9e est essentielle pour former les Aptamarkers \u00e0 reconna\u00eetre des biomarqueurs sp\u00e9cifiques associ\u00e9s \u00e0 la r\u00e9ponse au traitement ou aux r\u00e9actions ind\u00e9sirables.<\/p>\n<h2>Le criblage rentable par le biais de tests de qPCR<\/h2>\n<p>Une fois que les Aptamarkers sont form\u00e9s, leur transformation en un simple test de r\u00e9action en cha\u00eene par polym\u00e9rase quantitative (qPCR) devient une innovation majeure. Cette transformation permet un processus de d\u00e9pistage rentable et efficace pour les individus participant aux essais cliniques. Le test de qPCR, bas\u00e9 sur la biblioth\u00e8que Aptamarker, agit comme un outil de diagnostic, fournissant rapidement des informations sur la probabilit\u00e9 qu'un individu r\u00e9ponde favorablement au traitement ou qu'il subisse des effets ind\u00e9sirables.<\/p>\n<h2>Ajustement des crit\u00e8res d'inclusion et d'exclusion<\/h2>\n<p><em>Crit\u00e8res d'inclusion :<\/em><\/p>\n<p>Les capacit\u00e9s pr\u00e9dictives d'Aptamarker permettent aux chercheurs d'identifier les individus pr\u00e9dispos\u00e9s \u00e0 des r\u00e9ponses positives au traitement. En criblant les participants potentiels en fonction du test qPCR Aptamarker, les essais cliniques peuvent \u00eatre con\u00e7us pour inclure des personnes plus susceptibles de b\u00e9n\u00e9ficier du traitement, am\u00e9liorant ainsi le taux de r\u00e9ussite global de l'essai et optimisant l'utilisation des ressources.<\/p>\n<p><em>Crit\u00e8res d'exclusion :<\/em><\/p>\n<p>Inversement, le d\u00e9pistage par Aptamarker peut identifier les personnes susceptibles de pr\u00e9senter des effets secondaires ind\u00e9sirables ou de ne pas r\u00e9pondre au traitement. Cette approche d'exclusion met l'accent sur la s\u00e9curit\u00e9 des participants et simplifie le processus des essais cliniques en \u00e9liminant les candidats moins susceptibles de b\u00e9n\u00e9ficier du traitement. Cela am\u00e9liore non seulement le profil de s\u00e9curit\u00e9 global de l'essai, mais contribue \u00e9galement \u00e0 rendre le processus de d\u00e9veloppement de m\u00e9dicaments plus efficace et rentable.<\/p>\n<h2>Repositionnement des essais cliniques pour diff\u00e9rentes indications<\/h2>\n<p>La flexibilit\u00e9 d'Aptamarker va au-del\u00e0 de la conception initiale des essais. Les informations obtenues \u00e0 partir du profilage biomol\u00e9culaire des participants peuvent faciliter le repositionnement des essais cliniques pour diff\u00e9rentes indications. En comprenant les r\u00e9ponses uniques au sein d'une population, les chercheurs peuvent explorer d'autres applications th\u00e9rapeutiques sans repartir de z\u00e9ro, ce qui pourrait acc\u00e9l\u00e9rer le d\u00e9veloppement de traitements pour diverses affections.<\/p>\n<p>En conclusion, la plateforme Aptamarker de NeoVentures Biotechnology red\u00e9finit l'avenir des essais cliniques. En introduisant une dimension personnalis\u00e9e et pr\u00e9dictive aux crit\u00e8res d'inclusion et d'exclusion, les Aptamarkers apportent un niveau de pr\u00e9cision qui \u00e9tait autrefois inimaginable. Cette approche am\u00e9liore non seulement l'efficacit\u00e9 et les taux de r\u00e9ussite des essais cliniques, mais garantit \u00e9galement un processus de d\u00e9veloppement de m\u00e9dicaments plus s\u00fbr et plus rentable. Alors que nous entrons dans l'\u00e8re des Aptamarkers, nous nous engageons dans un voyage vers une nouvelle norme de m\u00e9decine personnalis\u00e9e et d'interventions th\u00e9rapeutiques cibl\u00e9es, faisant ainsi progresser les fronti\u00e8res de l'innovation en mati\u00e8re de sant\u00e9.<\/p>","protected":false},"excerpt":{"rendered":"<p>NeoVentures Biotechnology&#8217;s Aptamarker platform revolutionizes clinical trials by introducing personalized and predictive inclusion and exclusion criteria. Aptamarkers are trained using biological samples and participants&#8217; treatment responses, enabling a cost-effective qPCR test for screening individuals entering clinical trials. The predictive capabilities of Aptamarkers allow researchers to tailor inclusion criteria for positive treatment responses and exclusion criteria&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" rel=\"bookmark\">Lire la suite &raquo;<span class=\"screen-reader-text\">Cas d'Utilisation d'Aptamarqueur : Am\u00e9liorer les Essais Cliniques avec la Pr\u00e9cision d'Aptamarqueur - Personnaliser les Crit\u00e8res d'Inclusion et d'Exclusion<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5644,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8,39,1],"tags":[],"class_list":["post-5642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers","category-case-studies","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria<\/title>\n<meta name=\"description\" content=\"Explore NeoVentures&#039; Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\" \/>\n<meta property=\"og:description\" content=\"Explore NeoVentures&#039; Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-01T17:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T18:30:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1456\" \/>\n\t<meta property=\"og:image:height\" content=\"816\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\",\"datePublished\":\"2023-12-01T17:02:25+00:00\",\"dateModified\":\"2026-04-08T18:30:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"},\"wordCount\":645,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"articleSection\":[\"Aptamers\",\"Case Studies\",\"Uncategorized\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\",\"name\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"datePublished\":\"2023-12-01T17:02:25+00:00\",\"dateModified\":\"2026-04-08T18:30:58+00:00\",\"description\":\"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp\",\"width\":1456,\"height\":816,\"caption\":\"image of an aptamer under a microscope\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cas d'Utilisation d'Aptamarqueur : Am\u00e9liorer les Essais Cliniques avec la Pr\u00e9cision d'Aptamarqueur - Personnaliser les Crit\u00e8res d'Inclusion et d'Exclusion","description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","og_locale":"fr_FR","og_type":"article","og_title":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria","og_description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","og_url":"https:\/\/neoaptamers.com\/fr\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","og_site_name":"neoaptamers","article_published_time":"2023-12-01T17:02:25+00:00","article_modified_time":"2026-04-08T18:30:58+00:00","og_image":[{"width":1456,"height":816,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","type":"image\/webp"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Gregory Penner","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria","datePublished":"2023-12-01T17:02:25+00:00","dateModified":"2026-04-08T18:30:58+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"},"wordCount":645,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","articleSection":["Aptamers","Case Studies","Uncategorized"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","url":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/","name":"Cas d'Utilisation d'Aptamarqueur : Am\u00e9liorer les Essais Cliniques avec la Pr\u00e9cision d'Aptamarqueur - Personnaliser les Crit\u00e8res d'Inclusion et d'Exclusion","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","datePublished":"2023-12-01T17:02:25+00:00","dateModified":"2026-04-08T18:30:58+00:00","description":"Explore NeoVentures' Aptamarker platform, enhancing clinical trials with personalized, predictive criteria for safety and efficiency.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/11\/lbteam._scientifically_correct_image_of_an_aptamer_under_a_micr_07486015-7856-40bc-b3a7-1974c1759293.webp","width":1456,"height":816,"caption":"image of an aptamer under a microscope"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/aptamarker-use-case-enhancing-clinical-trials-with-aptamarker-precision-tailoring-inclusion-and-exclusion-criteria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Aptamarker Use Case: Enhancing Clinical Trials with Aptamarker Precision \u2013 Tailoring Inclusion and Exclusion Criteria"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=5642"}],"version-history":[{"count":1,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5642\/revisions"}],"predecessor-version":[{"id":5643,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5642\/revisions\/5643"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media\/5644"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=5642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/categories?post=5642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/tags?post=5642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}